closeEGRIFTA SV® Personal Assistant
DownloadPatient InformationDownloadPrescribing Information
THERA patient support

There for You Every Step of the Way

THERA patient support® is a comprehensive patient support program offering personalized services and a dedicated team that will support you at every step of your EGRIFTA SV® treatment journey.

Doctors discussing patients
Patients icon

Our Patient Care Coordinators Can:

  • Enroll you in the EGRIFTA SV® Co-Pay Assistance Program and verify your eligibility
  • Identify your best insurance and coverage options
  • Follow up about your insurance benefits
  • Find specialty pharmacies in your insurance network
  • Help you get ready for therapy with educational materials and supplies
Nurses icon

Our Nurse Navigators Can:

  • Train you how to properly mix and inject EGRIFTA SV®
  • Share advice for starting and staying on therapy
  • Answer common therapy-related questions throughout your treatment
  • Provide financial assistance, resources, and information regardless of the type of insurance you have

Once your healthcare provider has prescribed you EGRIFTA SV®, call THERA patient support® at 1-833-23-THERA (1-833-238-4372) and make sure you are enrolled in the program.

Learn more about the program by downloading the THERA patient support® brochure.

Download

Keep Exploring This Page to Find Useful Tools and Resources to Help You on Your EGRIFTA SV® Journey.

Start the Conversation

Before you visit your healthcare provider to talk about excess visceral abdominal fat and EGRIFTA SV®, you should ask yourself some questions.

The Doctor Discussion Guide provides some questions and can help guide the conversation with your healthcare provider.

Stock photography. Posed by model.

Learn How to Administer EGRIFTA SV®

If you have already been prescribed EGRIFTA SV®, download the EGRIFTA SV® STEP-BY-STEP ADMINISTRATION GUIDE, or watch the video to learn how to prepare and inject EGRIFTA SV®.

IMPORTANT PATIENT INFORMATION ABOUT EGRIFTA SV® (TESAMORELIN) FOR INJECTION

Expand

What is EGRIFTA SV® (tesamorelin) for injection?

  • EGRIFTA SV® is an injectable prescription medicine used to reduce excess abdominal fat in adults with HIV and lipodystrophy. EGRIFTA SV® is a growth hormone-releasing factor (GHRF) analog.
  • EGRIFTA SV® is not for weight loss management.
  • The long-term safety of EGRIFTA SV® on the heart and blood vessels (cardiovascular) is not known.
  • It is not known whether taking EGRIFTA SV® helps improve how well you take your antiretroviral medications.
  • It is not known if EGRIFTA SV® is safe and effective in children; do not use in children.

You should not take EGRIFTA SV® if you:

  • Have a pituitary gland tumor, surgery, or other problems related to your pituitary gland, or have had radiation treatment to your head or head injury.
  • Have active cancer.
  • Are allergic to tesamorelin or any of the ingredients in EGRIFTA SV®.
  • Are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA SV® and talk with your healthcare provider.
  • Are less than 18 years of age.

Before using EGRIFTA SV®, tell your healthcare provider if you:

  • Have or have had cancer.
  • Have problems with blood sugar or diabetes.
  • Have scheduled heart or stomach surgery.
  • Have breathing problems.
  • Are breastfeeding or plan to breastfeed.
  • Are taking any other prescription and non-prescription medicines, vitamins, and herbal supplements.

EGRIFTA SV® may cause serious side effects including:

  • Increased risk of new cancer in adults with HIV or your cancer coming back (reactivation). Stop using EGRIFTA SV® and inform your healthcare provider if any cancer symptoms come back.
  • Increased levels of your insulin-like growth factor-1 (IGF-1). Your healthcare provider will do blood tests to check your IGF-1 levels while you are taking EGRIFTA SV®.
  • Serious allergic reaction such as rash or hives anywhere over the body or on the skin, swelling of the face or throat, shortness of breath or trouble breathing, fast heartbeat, feeling of faintness or fainting, itching and reddening or flushing of the skin. If you have any of these symptoms, stop using EGRIFTA SV® and get emergency medical help right away.
  • Swelling or fluid retention. Call your healthcare provider if you have swelling, an increase in joint pain, or pain or numbness in your hands or wrist.
  • Increase in blood sugar (glucose) or diabetes.
  • Injection site reactions. Injection site reactions are a common side effect of EGRIFTA SV®, but may sometimes be serious.
  • Increased risk of death in people who have critical illness because of heart or stomach surgery, trauma or serious breathing (respiratory) problems has been reported after treatment with therapeutic doses of growth hormones.

The most common side effects of EGRIFTA SV® include:

  • Pain in legs and arms
  • Muscle pain

These are not all of the possible side effects of EGRIFTA SV®. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to THERA patient support® toll-free at 1-833-23THERA (1-833-238-4372).

This information is not intended to replace discussions with your doctor. For additional information about EGRIFTA SV®, see the full Prescribing Information, Patient Information, Patient Instructions for Use, and talk to your doctor. For more information about EGRIFTA SV® contact THERA patient support® toll-free at 1-833-23THERA (1-833-238-4372).